Elusys Therapeutic Inc - Company & Market Research Reports

Elusys Therapeutics is a biopharmaceutical company founded in Pine Brook, New Jersey in 1998. The company specializes in the development of antibodies for the treatment infectious diseases. Elusys is engaged in the development of new therapies for the treatment of anthrax exposure following a natural or intentional release of anthrax spores. In particular, Elusys is currently focusing on late-stage clinical trials of Anthim (Obiltoxaximab) to be used for treatment and prevention of inhaled anthrax.


Antibody Discovery: Services and Platforms, 2017-2027 - Product Thumbnail Image

Antibody Discovery: Services and Platforms, 2017-2027

  • Report
  • 306 Pages
From
Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030 - Product Thumbnail Image

Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030

  • Report
  • 224 Pages
From
Large Volume Wearable Injectors Market (3rd Edition), 2017-2027 - Product Thumbnail Image

Large Volume Wearable Injectors Market (3rd Edition), 2017-2027

  • Report
  • 365 Pages
From
Bolus Injectors Market, 2014 - 2024 - Product Thumbnail Image

Bolus Injectors Market, 2014 - 2024

  • Report
  • 179 Pages
From
Anthrax Global Clinical Trials Review, H1, 2017 - Product Thumbnail Image

Anthrax Global Clinical Trials Review, H1, 2017

  • Clinical Trials
  • 69 Pages
From
Elusys Therapeutics, Inc Company Profile - Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis - Product Thumbnail Image

Elusys Therapeutics, Inc Company Profile - Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

  • Company Profile
  • 30 Pages
From
  • 6 Results (Page 1 of 1)
Loading Indicator
adroll